Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 7,056,852 shares, a decline of 18.3% from the November 15th total of 8,642,021 shares. Approximately 4.6% of the company’s stock are short sold. Based on an average daily volume of 3,150,140 shares, the short-interest ratio is currently 2.2 days.

Shares of Achillion Pharmaceuticals (ACHN) opened at $2.76 on Monday. Achillion Pharmaceuticals has a 1 year low of $2.69 and a 1 year high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. During the same quarter in the prior year, the company earned ($0.15) earnings per share. equities research analysts anticipate that Achillion Pharmaceuticals will post -0.63 earnings per share for the current fiscal year.

In related news, major shareholder & Johnson Johnson sold 18,367,346 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $2.75, for a total transaction of $50,510,201.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 7.24% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Achillion Pharmaceuticals by 3.6% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 800 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Achillion Pharmaceuticals by 18.6% during the 2nd quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 4,144 shares during the period. Legal & General Group Plc boosted its holdings in shares of Achillion Pharmaceuticals by 53.8% during the 2nd quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock worth $196,000 after buying an additional 15,000 shares during the period. Voya Investment Management LLC boosted its holdings in shares of Achillion Pharmaceuticals by 13.7% during the 2nd quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 6,730 shares during the period. Finally, Bank of Montreal Can boosted its holdings in shares of Achillion Pharmaceuticals by 6.4% during the 2nd quarter. Bank of Montreal Can now owns 56,715 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 3,410 shares during the period. 76.93% of the stock is owned by institutional investors and hedge funds.

Several research firms have commented on ACHN. Robert W. Baird reissued a “neutral” rating and issued a $4.00 target price (down from $5.00) on shares of Achillion Pharmaceuticals in a research report on Tuesday, September 12th. ValuEngine downgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Monday, September 11th. Chardan Capital reissued a “neutral” rating on shares of Achillion Pharmaceuticals in a research report on Sunday, September 17th. Leerink Swann reissued a “buy” rating and issued a $5.00 target price on shares of Achillion Pharmaceuticals in a research report on Monday, December 11th. Finally, Zacks Investment Research downgraded shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. Achillion Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $5.13.

TRADEMARK VIOLATION NOTICE: “Achillion Pharmaceuticals, Inc. (ACHN) Short Interest Down 18.3% in November” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/12/18/achillion-pharmaceuticals-inc-achn-short-interest-down-18-3-in-november.html.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Receive News & Stock Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related stocks with our FREE daily email newsletter.